The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Latigo Biotherapeutics raises 150 million dollars for non-opioid pain treatments
Latigo Biotherapeutics has secured USD 150 million in Series B funding, led by Blue Owl Capital, with significant participation from the Qatar Investment Authority (QIA) and other investors. The funding will accelerate the development of Latigo's selective Nav1.8 inhibitors for non-opioid pain treatment and expand its drug pipeline. CEO Nima Farzan emphasized the urgent need for innovative non-opioid pain solutions, highlighting the potential to transform the treatment landscape.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.